Arginine vasopressin and oxytocin responses to angiotensin II are mediated by AT1 receptor subtype in normal men.
This study was performed to determine whether the stimulatory effect of plasma angiotensin II (ANG II) on arginine vasopressin (AVP) and oxytocin (OT) secretion in humans is mediated by AT1 subtype receptors. For this purpose, the effects of the AT1 receptor antagonist losartan (50 mg orally) or a placebo on the AVP and OT responses to ANG II (intravenous infusion for 60 minutes of successively increasing doses of 4, 8, and 16 ng/kg min; each dose for 20 minutes) administration were evaluated in seven normal men. In additional experiments, the same subjects were tested with losartan (50 mg orally) alone or placebo alone. Neither losartan nor placebo given alone modified the basal levels of AVP and OT. ANG II infusion induced significant increments in both serum AVP and OT levels (mean peaks were 1.55 and 1.41 times higher than baseline, respectively). Both hormonal responses to ANG II were completely abolished by pretreatment with losartan. These data provide evidence of AT1 receptor involvement in mediation of the ANG II-stimulating effect on AVP and OT secretion.
Department of Internal Medicine, School of Medicine, University of Parma, Italy.
P
P
Chiodera
R
R
Volpi
A
A
Caiazza
N
N
Giuliani
M G
MG
Magotti
V
V
Coiro
D000328:Adult; D000804:Angiotensin II / Q000097:blood*; D057911:Angiotensin Receptor Antagonists; D001127:Arginine Vasopressin / Q000097:blood* / Q000378:metabolism; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D019808:Losartan / Q000008:administration & dosage*; D008297:Male; D010121:Oxytocin / Q000097:blood* / Q000378:metabolism; D012016:Reference Values
D057911:Angiotensin Receptor Antagonists; D000804:Angiotensin II; D001127:Arginine Vasopressin; D010121:Oxytocin; D019808:Losartan